

Income statement

Three months ended 31 March 2017

	Total £m	Total \$m
TURNOVER	7,384	9,230
Cost of sales	(2,513)	(3,141)
Gross profit	4,871	6,089
Selling, general and administration	(2,452)	(3,065)
Research and development	(960)	(1,200)
Royalty income	82	103
Other operating income/(expense)	177	221
OPERATING PROFIT	1,718	2,148
Finance income	21	26
Finance expense	(194)	(242)
Share of after tax profits of joint ventures and associates	5	6
PROFIT BEFORE TAXATION	1,550	1,938
Taxation	(327)	(409)
PROFIT AFTER TAXATION FOR THE PERIOD	1,223	1,529
Profit attributable to non-controlling interests	177	221
Profit attributable to shareholders	1,046	1,308
	1,223	1,529
EARNINGS PER SHARE	21.4p	26.8¢
Diluted earnings per share	21.3p	26.6¢

US dollar amounts shown above are a convenience translation of the sterling amounts.

Pharmaceuticals turnover - three months ended 31 March 2017

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Respiratory	1,683	767	382	534	2,104	959	477	668
<i>Anoro Ellipta</i>	62	40	14	8	78	50	18	10
<i>Armuity Ellipta</i>	8	8	-	-	10	10	-	-
<i>Avamys/Veramyst</i>	91	-	21	70	114	-	26	88
<i>Flixotide/Flovent</i>	164	89	28	47	205	111	35	59
<i>Incruse Ellipta</i>	34	20	10	4	43	25	13	5
<i>Nucala</i>	59	42	11	6	74	53	13	8
<i>Relvar/Breo Ellipta</i>	204	111	49	44	255	139	61	55
<i>Seretide/Advair</i>	752	339	206	207	940	424	257	259
<i>Ventolin</i>	214	117	35	62	267	146	44	77
Other	95	1	8	86	118	1	10	107
HIV	985	608	259	118	1,231	760	324	147
<i>Epzicom/Kivexa</i>	78	14	39	25	97	17	49	31
<i>Selzentry</i>	38	20	10	8	48	25	13	10
<i>Tivicay</i>	301	200	70	31	376	250	87	39
<i>Triumeq</i>	539	360	134	45	674	450	168	56
Other	29	14	6	9	36	18	7	11
Immuno-inflammation	92	84	6	2	115	105	7	3
<i>Benlysta</i>	91	83	6	2	114	104	7	3
Established Pharmaceuticals	1,429	272	361	796	1,786	340	451	995
Cardiovascular, metabolic and urology (CVMU)	216	58	86	72	270	72	108	90
<i>Avodart</i>	160	5	83	72	200	6	104	90
<i>Eperzan/Tanzeum</i>	28	28	1	(1)	35	35	1	(1)
Other	28	25	2	1	35	31	3	1
Established products	640	191	132	317	800	239	165	396
<i>Coreg</i>	35	35	-	-	44	44	-	-
<i>Imigran/Imitrex</i>	53	30	16	7	66	37	20	9
<i>Lamictal</i>	166	89	26	51	207	111	32	64
<i>Requip</i>	27	4	6	17	34	5	8	21
<i>Serevent</i>	26	15	9	2	33	19	11	3
<i>Seroxat/Paxil</i>	45	-	9	36	56	-	11	45
<i>Valtrex</i>	31	4	7	20	39	5	9	25
<i>Zeffix</i>	26	-	1	25	32	-	1	31
Other	231	14	58	159	289	18	73	198
Other pharmaceuticals	573	23	143	407	716	29	178	509
Dermatology	113	-	41	72	141	-	51	90
<i>Augmentin</i>	155	-	53	102	194	-	66	128
Other anti-bacterials	48	1	17	30	60	1	21	38
Rare diseases	110	14	37	59	137	18	46	73
Oncology	20	-	-	20	25	-	-	25
Other	127	8	(5)	124	159	10	(6)	155
Pharmaceuticals	4,189	1,731	1,008	1,450	5,236	2,164	1,259	1,813

Vaccines turnover - three months ended 31 March 2017

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Meningitis	191	46	104	41	239	58	130	51
<i>Bexsero</i>	126	27	83	16	158	34	104	20
<i>Menveo</i>	55	19	16	20	69	24	20	25
<i>Other</i>	10	-	5	5	12	-	6	6
Influenza	13	(3)	1	15	16	(4)	1	19
<i>Fluarix, FluLaval</i>	13	(3)	1	15	16	(4)	1	19
Established Vaccines	948	320	284	344	1,185	400	355	430
<i>Infanrix, Pediarix</i>	234	125	83	26	292	156	104	32
<i>Boostrix</i>	111	54	39	18	139	67	49	23
Hepatitis	167	85	51	31	209	106	64	39
<i>Rotarix</i>	146	54	22	70	183	68	27	88
<i>Synflorix</i>	133	-	14	119	166	-	17	149
<i>Priorix, Priorix Tetra, Varilrix</i>	77	-	37	40	96	-	46	50
<i>Cervarix</i>	17	-	7	10	21	-	9	12
<i>Other</i>	63	2	31	30	79	3	39	37
Vaccines	1,152	363	389	400	1,440	454	486	500

Consumer Healthcare turnover - three months ended 31 March 2017

	Total £m	Total \$m
Wellness	1,070	1,337
Oral health	628	785
Nutrition	182	228
Skin health	163	204
	2,043	2,554
	Total £m	Total \$m
US	527	659
Europe	605	756
International	911	1,139
	2,043	2,554

Balance sheet

	31 March 2017 £m	31 March 2017 \$m
ASSETS		
Non-current assets		
Property, plant and equipment	10,812	13,515
Goodwill	5,960	7,450
Other intangible assets	18,753	23,441
Investments in associates and joint ventures	276	345
Other investments	1,049	1,311
Deferred tax assets	4,351	5,439
Other non-current assets	1,247	1,559
Total non-current assets	42,448	53,060
Current assets		
Inventories	5,417	6,771
Current tax recoverable	227	284
Trade and other receivables	6,224	7,780
Derivative financial instruments	124	155
Liquid investments	88	110
Cash and cash equivalents	4,509	5,636
Assets held for sale	198	248
Total current assets	16,787	20,984
TOTAL ASSETS	59,235	74,044
LIABILITIES		
Current liabilities		
Short-term borrowings	(3,740)	(4,675)
Contingent consideration liabilities	(595)	(744)
Trade and other payables	(12,033)	(15,041)
Derivative financial instruments	(168)	(210)
Current tax payable	(1,414)	(1,768)
Short-term provisions	(807)	(1,009)
Total current liabilities	(18,757)	(23,447)
Non-current liabilities		
Long-term borrowings	(14,600)	(18,250)
Deferred tax liabilities	(1,965)	(2,456)
Pensions and other post-employment benefits	(3,885)	(4,856)
Other provisions	(658)	(823)
Derivative financial instruments	(1)	(1)
Contingent consideration liabilities	(5,199)	(6,499)
Other non-current liabilities	(8,577)	(10,721)
Total non-current liabilities	(34,885)	(43,606)
TOTAL LIABILITIES	(53,642)	(67,053)
NET ASSETS	5,593	6,991
EQUITY		
Share capital	1,343	1,679
Share premium account	2,995	3,744
Retained earnings	(4,906)	(6,133)
Other reserves	2,282	2,852
Shareholders' equity	1,714	2,142
Non-controlling interests	3,879	4,849
TOTAL EQUITY	5,593	6,991

US dollar amounts shown above are a convenience translation of the sterling amounts.